FAAH
Inhibitory Selectivity
FAAH Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2631 |
URB597URB597 (KDS-4103) is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets. Phase 1. |
||
| S2666 |
PF-3845PF-3845 is a potent, selective and irreversible FAAH inhibitor with Ki of 230 nM, showing negligible activity against FAAH2. |
||
| S0497 |
JNJ-42165279JNJ-42165279 (JNJ-5279) is an inhibitor of fatty acid amide hydrolase (FAAH) that inhibits recombinant human and rat FAAH with IC50 of 70 nM and 313 nM, respectively. |
||
| S5329 |
FAAH-IN-2FAAH-IN-2 is an inhibitor of fatty acid amide hydrolase (FAAH). |
||
| S6609 |
JZL195JZL195 is a potent inhibitor of both FAAH and MAGL with IC50s of 2 and 4 nM respectively. |
||
| S3586 |
URB937URB937 is an orally active and peripherally restricted FAAH inhibitor with IC50 of 26.8 nM and increases anandamide levels. |
||
| S2421 |
PF-04457845PF-04457845 (PF-4457845) is a potent, favorable selective inhibitor of Fatty acid amide hydrolase (FAAH) with IC50 of 7.2 nM and 7.4 nM for hFAAH and rFAAH, respectively. PF-04457845 covalently modifies the active-site serine nucleophile of FAAH with exquisite selectivity relative to other members of the serine hydrolase superfamily. |
||
| S8052 |
LY-2183240LY-2183240 is a potent, covalent inhibitor of the EC-degrading enzyme fatty acid amide hydrolase (FAAH). LY-2183240 disrupts the cellular uptake of the lipid endocannabinoid (EC) anandamide and promote analgesia in vivo. LY-2183240 is also an inhibitor of monoacylgylcerol lipase (MGL). |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2631 |
URB597URB597 (KDS-4103) is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets. Phase 1. |
||
| S2666 |
PF-3845PF-3845 is a potent, selective and irreversible FAAH inhibitor with Ki of 230 nM, showing negligible activity against FAAH2. |
||
| S0497 |
JNJ-42165279JNJ-42165279 (JNJ-5279) is an inhibitor of fatty acid amide hydrolase (FAAH) that inhibits recombinant human and rat FAAH with IC50 of 70 nM and 313 nM, respectively. |
||
| S5329 |
FAAH-IN-2FAAH-IN-2 is an inhibitor of fatty acid amide hydrolase (FAAH). |
||
| S6609 |
JZL195JZL195 is a potent inhibitor of both FAAH and MAGL with IC50s of 2 and 4 nM respectively. |
||
| S3586 |
URB937URB937 is an orally active and peripherally restricted FAAH inhibitor with IC50 of 26.8 nM and increases anandamide levels. |
||
| S2421 |
PF-04457845PF-04457845 (PF-4457845) is a potent, favorable selective inhibitor of Fatty acid amide hydrolase (FAAH) with IC50 of 7.2 nM and 7.4 nM for hFAAH and rFAAH, respectively. PF-04457845 covalently modifies the active-site serine nucleophile of FAAH with exquisite selectivity relative to other members of the serine hydrolase superfamily. |
||
| S8052 |
LY-2183240LY-2183240 is a potent, covalent inhibitor of the EC-degrading enzyme fatty acid amide hydrolase (FAAH). LY-2183240 disrupts the cellular uptake of the lipid endocannabinoid (EC) anandamide and promote analgesia in vivo. LY-2183240 is also an inhibitor of monoacylgylcerol lipase (MGL). |
